Humanoid robots are entering the deployment validation phase, but a "public relations problem" may become a key bottleneck

Overview

This report is an update in Morgan Stanley's humanoid robot series, with the core question being whether the robotics industry has a public communication and social acceptance challenge. The report argues that humanoid robot commercialization is accelerating, with progress in financing, policy, manufacturing capacity, supply chain, and use cases, especially driven by Chinese policy and corporate deployment. But the industry remains at an early stage, and real commercial value still needs to be validated through ROI, operating data, and repeat purchases. Social factors such as labor relations, employment narratives, regulatory restrictions, and supply chain security may be just as important as technical performance.

Core views

First, humanoid robots should not be simply described as worker substitutes; social license and labor communication may determine the pace of deployment. Second, manufacturing capability is being built ahead of demand; capacity expansion helps reduce costs and improve reliability, but should not be directly equated with sales. Third, commercial adoption is moving from demonstrations toward structured scenarios such as manufacturing, logistics, inspection, retail, and public services, but is still mainly at the pilot and scenario-validation stage. Fourth, the AI path is still evolving rapidly, and long-term advantage is more likely to come from real operating data, rapid iteration capability, and tight hardware-software integration rather than any single model architecture. Fifth, Chinese policy, financing, and supply-chain activity provide incremental catalysts for the industry, but potential U.S. protectionism may reshape the global competitive landscape.

Analysis framework

The report uses ecosystem tracking and thematic research, combining policy events, financing cases, manufacturing capacity build-out, commercial deployment, supply-chain stock performance, patent data, and long-term TAM/adoption-rate estimates to provide a multidimensional update on the progress of the humanoid robotics industry. The analysis focuses not on the financial model of any single company, but on industry diffusion, real deployment validation, supply-chain beneficiaries, and potential risks.

Methodology notes

• Industry diffusionTechnology diffusion and adoption curve

  From demonstration to real deployment

  The report views humanoid robots as a technology still in the early stage of diffusion, emphasizing a shift from demo videos, pilot partnerships, and capacity targets toward verifiable operating hours, repeat purchases, and customer payback periods.

• Market opportunityTAM and adoption-rate scenario estimation

  Long-term global humanoid robot adoption estimate

  The report uses assumptions for global potential adoption volume and average selling price to estimate long-term market size, and provides adoption milestones for 2036, 2040, 2044, and 2050.

• Competitive advantageData flywheel

  Deploy, collect data, improve models, redeploy

  The report believes the AI path is not yet fixed, and long-term advantage may come from real-world operating data, post-training capability, task decomposition, quality evaluation, and tight hardware-software integration.

• Policy and social riskSocial license and regulatory restrictions

  Labor relations, employment narratives, and cross-border restrictions

  The Hyundai union's reaction to Atlas entering the production line, along with the introduction of the U.S. GUARD Act, shows that humanoid robot adoption depends not only on technology and cost, but also on social acceptance and national security review.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Humanoid 100 global humanoid robotics enabler portfolio

  Represents Morgan Stanley's tracked global pool of listed supply-chain and technology beneficiary assets

  Strengths

  Strong equal-weighted performance since inception, covering semiconductors, electronics, industrial automation, materials, and core components.

  Weaknesses

  The portfolio is not a complete index, and some companies still have limited revenue exposure to humanoid robots.

  Comparison

  Outperformed the S&P 500, MSCI Europe, and MSCI China, but lagged MSCI Korea and MSCI Taiwan.

  Risks

  Theme enthusiasm fading, insufficient real orders, valuations pulled forward too much, and low supply-chain revenue contribution.

• China humanoid robot value chain

  Covers 45 related stocks across the brain, body components, and complete-system integration

  Strengths

  Policy support, dense supply chain, and companies accelerating mass production and listing preparation, with potential to build a closed loop of deployment data.

  Weaknesses

  Short-term performance is under pressure, commercial demand still needs validation, and some orders may be primarily for research, education, or demonstration purposes.

  Comparison

  Equal-weighted down 11% MTD in July, lagging MSCI China.

  Risks

  Weak AI-sector sentiment, insufficient capacity utilization, price competition, and U.S. trade and security reviews.

• Hesai Group / HSAI.US

  Added to Humanoid 100 and positioned as a beneficiary in LiDAR and robot actuator modules

  Strengths

  Has an ADAS pipeline from automakers including Li Auto, Xiaomi, Leapmotor, BYD, Geely, and Changan, while expanding into robotaxi and humanoid robot opportunities.

  Weaknesses

  Humanoid robot-related revenue is still at an early stage, and upside over the next 12-18 months requires order conversion.

  Comparison

  To add HSAI, the report removed ORCL from the list on the grounds of relatively lower relevance to the investment story.

  Risks

  Cyclicality in automotive LiDAR, slower-than-expected robot volume ramp, and changes in gross margin and cost-plus model dynamics.

• Tesla Optimus

  Represents manufacturing capability build-out by a leading U.S. humanoid robot OEM

  Strengths

  Fremont is preparing a dedicated Optimus production line, with a high long-term designed capacity target.

  Weaknesses

  At present this is more about capacity preparation than proof of near-term shipments, yield, or demand.

  Comparison

  Along with XPeng and Boston Dynamics, it is a representative case of building manufacturing capacity ahead of time.

  Risks

  Mass-production delays, cost and reliability falling short, and unclear customer ROI.

• Unitree and China's low-cost robot platforms

  Viewed by the report as one of the low-cost research platforms widely used by U.S. research labs

  Strengths

  Low cost and high availability help research institutions carry out model training and experimentation.

  Weaknesses

  If U.S. regulation expands, imports and component cooperation may be restricted.

  Comparison

  The GUARD Act could create a policy environment similar to restrictions on Chinese drones.

  Risks

  U.S. market access risk, national security review, and rising supply-chain substitution costs.

Key data

• China 2026 humanoid robot shipment forecast50,000 unitsMorgan Stanley raised its forecast from 28,000 units to 50,000 units.
• China 2030 humanoid robot shipment forecast446,000 unitsThe report believes OEMs, enterprise users, and the government are driving commercial validation and adoption.
• China policy deployment targetBy the end of 2026, deployment capability at the 10,000-unit level and more than 100 high-value applicationsRelevant initiatives from the Ministry of Industry and Information Technology and the State-owned Assets Supervision and Administration Commission are application-scenario oriented, requiring local governments and central SOEs to identify operating sites.
• Long-term global adoption estimateAbout 28.1 million units in 2036, about 138.5 million units in 2040, about 430 million units in 2044, and about 1 billion units in 2050Corresponding to phased penetration toward a long-term potential total of about 1 billion units.
• Humanoid 100 performanceEqual-weighted up 44% since inception on 2025-02-06Outperformed the S&P 500, MSCI Europe, and MSCI China, but lagged MSCI Korea and MSCI Taiwan.
• China humanoid robot value chain performanceEqual-weighted down 11% MTD in JulyPerformance lagged MSCI China due to weakness in the AI sector and the market waiting for production updates from leading OEMs.
• 2026 global humanoid robot venture financingAs of 2026-07-15, already exceeded the full-year total for 2025Based on financing for companies classified by PitchBook as Humanoid Robotics.
• Distribution of global humanoid patent offices over the past five yearsChina 8,629 cases, United States 1,659 cases, Japan 1,105 cases, WIPO 1,105 casesThe report shows the top 20 patent offices, with China clearly leading in volume.
• Walden Robotics financing$300 million seed round, valued at $1.1 billionCo-led by Toyota and Deviation Capital, positioned as a general-purpose robotics company for manufacturing and logistics.
• Agility Robotics potential SPAC transactionTransaction valuation of about $2.5 billion, expected gross proceeds of more than $620 millionStill subject to SEC review, shareholder approval, redemption, and other closing conditions.

Impact & implications

For investing, the report suggests that the humanoid robot theme still has long-term opportunity, but short-term pricing should place greater emphasis on the quality of commercialization rather than concept heat. Across the supply chain, LiDAR, actuators, motors, sensors, reducers, batteries, semiconductors, manufacturing, and system integration may all benefit; however, valuations and order conversion depend on real deployment data. On policy, China's scenario-driven push helps form a closed data loop for deployment, while potential U.S. restrictions could protect domestic manufacturers but raise research and manufacturing costs. Socially, if the industry continues to frame the narrative mainly around job replacement, labor conflict and public resistance may slow adoption.

Risks

• Insufficient social acceptance: if humanoid robots are viewed as directly replacing workers, they may trigger unions, labor negotiations, and public backlash.
• Commercial ROI remains unproven: investors need to see operating hours, intervention rates, maintenance costs, repeat purchases, and customer payback periods, rather than demo videos.
• Capacity ahead of demand: Tesla, XPeng, Boston Dynamics, and others are building capacity, but factory capability does not equal near-term delivery, yield, or real demand.
• Uncertain AI path: industry model approaches are changing rapidly, no single architecture has clearly won out, and real-world data plus iteration capability are more likely to form a moat.
• U.S. protectionism: if the GUARD Act passes, it may restrict robots from China and related countries from entering the U.S. market, and affect R&D costs and supply-chain cooperation.
• China's policy targets are not fully equivalent to commercial demand: government-driven deployment helps pilots, but may not directly translate into sustainable commercial demand and attractive unit economics.
• Supply-chain valuation risk: theme-related stocks may already reflect long-term opportunity ahead of time, while near-term revenue contribution remains limited.

What to watch

• Productive operating hours and task completion rates after actual customer deployment over the next several quarters.
• Humanoid robot intervention rates, maintenance costs, failure rates, and customer payback periods.
• Repeat purchases after pilot programs, fleet expansion, and real paid orders, rather than non-binding partnership announcements.
• The pace of scenario rollout by provinces and central SOEs under China's policy targets, and whether a reusable closed data loop is formed.
• Progress of the U.S. GUARD Act and whether it evolves into a de facto import restriction.
• The gap between capacity build-out and actual shipments for Tesla Optimus, XPeng IRON, Boston Dynamics Atlas, and others.
• Changes in world models, model reasoning, post-training, and real-data collection capabilities in the humanoid robot AI path.
• Performance divergence and constituent changes between Humanoid 100 and China humanoid robot value-chain stocks.